CoorsTek Bioceramics has secured another legal victory in its dispute with CeramTec GmbH over trademark rights to the color pink for ceramic hip components, after the German Federal Patent Court upheld the cancellation of CeramTec's trademark in Germany. The court found that the application had been filed in bad faith with the intention of extending an expiring patent monopoly and keeping competitors out of the market. The decision matters because it addresses a practice in which color trademarks can be used to preserve market exclusivity after patent protection lapses, a concern with direct consequences for how orthopaedic ceramic components reach device makers and, ultimately, patients.
The ruling strengthens CoorsTek Bioceramics' ability to market its ceramic hip replacement components, including Permallon orthopaedic ceramics, in Germany. It also follows favorable decisions in France and the United States, suggesting a consistent judicial skepticism toward trademark claims that function as extensions of expired patent rights. For the orthopaedic supply chain, the outcome could widen the field of suppliers offering ceramic bearing surfaces for total joint arthroplasty, a segment where CoorsTek Bioceramics says more than six million of its components have been sold and distributed for clinical use since 2005.
CeramTec is appealing the decision, so the legal question is not fully settled. Still, CoorsTek is framing the ruling alongside its other court wins and OEM regulatory clearances as evidence that a more competitive orthopaedic ceramics supply chain is taking shape. The company's argument rests on the idea that competition in ceramic implant components benefits device manufacturers through broader sourcing options and supports continued innovation in bearing surfaces used in hip replacement procedures. The full announcement, including downloadable images and bios, can be viewed by those who click here.
CoorsTek Bioceramics is a wholly owned subsidiary of CoorsTek, Inc., and draws on more than 110 years of technical ceramics expertise. Its components are used not only in joint arthroplasty but also in implant devices for neurological, cardiological, spinal, and radiation applications. The parent company, founded in 1910 and continuously owned and operated by the Coors family, manufactures technical ceramics for medical, semiconductor, aerospace, energy, and other industries, with more than 400 proprietary material formulations and vertically integrated systems.
The broader implication is that intellectual property strategy in medical ceramics is under renewed scrutiny in Europe. A ruling that a color trademark was registered in bad faith to block competitors signals that courts may look past the formal scope of a trademark to its competitive purpose. For manufacturers and hospital buyers watching the cost and availability of orthopaedic implants, the German decision adds to a pattern of judgments across three major markets that could reshape how suppliers compete in ceramic hip components.
